Navigation Links
10th CyberKnife System Installed at an HCA Hospital
Date:6/24/2009

Centennial Medical Center Brings Benefits of Whole Body Radiosurgery to Nashville

SUNNYVALE, Calif., June 24 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the 10th CyberKnife(R) Robotic Radiosurgery System was installed at a Hospital Corporation of America (HCA) facility. The installation took place at The Sarah Cannon Cancer Center at Centennial Medical Center in Nashville, Tenn.

"The Sarah Cannon Cancer Center is proud to continue delivering on its promise to provide the highest quality, most advanced cancer treatment options in our region with the addition of the CyberKnife System," said Rocky Billups, administrator for The Sarah Cannon Cancer Center Network. "With this new image-guided robotic technology, we are giving new hope to those whose tumors were previously thought to be inoperable and untreatable."

This installation marks HCA's ninth installation in the United States. HCA's first international installation took place in London at The Harley Street Clinic in December 2008.

"Our relationship with HCA has provided an additional avenue for getting patients throughout the world access to the treatment benefits of radiosurgery," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The installation at Centennial Medical Center marks the first CyberKnife System in Nashville and enables local patients to conveniently receive outpatient treatment for their cancer right in their backyard."

About The Sarah Cannon Cancer Center Network

The Sarah Cannon Cancer Center Network--accredited by The Cancer Commission of the American College of Surgeons with commendations for providing superior cancer care -- is second to none in the Southeast for the diagnosis and treatment of cancer. With eight affiliated medical facilities, The Sarah Cannon Cancer Center Network has grown to become the largest community-based, privately-funded diagnostic and treatment center in the country.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 60,000 patients worldwide and currently more than 164 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to commercialization of products, clinical studies, and regulatory review and approval are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2008 fiscal year, as updated in our Form 10-Q filed on May 6, 2009 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869


'/>"/>
SOURCE Accuray
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Turkish Ministry of Health Purchases Two CyberKnife(R) Systems
2. CyberKnife Center of Miami Executive Director James G. Schwade M.D. Garners Ultimate Miami CEO Award
3. Dr. James Hevezi Appointed as Chief Physicist for CyberKnife Center of Miami
4. Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife
5. Presentations at Leading Neurosurgery Meeting Highlight Benefits of CyberKnife Radiosurgery for the Treatment of CNS Indications
6. CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide
7. First Patients Treated in India Using CyberKnife Radiosurgery
8. Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
9. Japan Treats First Extracranial Patients Using CyberKnife Radiosurgery
10. Clinical Evidence Grows in Support of CyberKnife Treatment for Intracranial and Extracranial Tumors
11. New Millennium CyberKnife in Brandon - Grand Opening Celebration on January 21, 2009 - Media Invited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Ohio (PRWEB) , ... December 09, 2016 , ... ... of miniature, folded, pharmaceutical inserts and outserts. As a means of expanding ... This addition will enable Flottman to individually code professional inserts (PIs) and patient ...
(Date:12/9/2016)... ... , ... Mediaplanet today announces distribution of the latest edition of “Transplants,” a ... as an organ donor for the 123,000 people in the United States who are ... up to 8 saves through organ donation and enhance many others through tissue donation, ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West ... January 1, 2017. The name change aligns the entire company with its ... health care quality. , “We are very proud of the achievements associated with ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing ... wellness program, at their world headquarters of Omni La Costa Resort & Spa in ... anyone seeking weight loss, personal development, a healthy lifestyle, or mental and physical healing. ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... -- RxWiki Inc., a digital health company that powers the ... of pharmacies through its Digital Pharmacist SaaS platform, today ... on Fire" Award in the Health and Life Sciences ... award as one of Austin,s fastest growing companies," said ... "Our platform gives independent retail pharmacies the digital tools ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 Summary ... to 2022", provides key market data on the Australia ... of US dollars, volume (in units) and average prices ... and YAG Lasers. The report also provides company ... market segements, and global corporate-level profiles of the key ...
Breaking Medicine Technology: